News2023-01-23
17 Views
" href="/article/news-provided-by-jcn-newswire/3770555/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-accepted-in-chinabr-">![]()
" href="/article/news-provided-by-jcn-newswire/3770555/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-accepted-in-chinabr-">Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China



NULL








